Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

CORAL GABLES, Fla., Aug. 9, 2022. Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials